Navelbine® (Vinorelbine) for Mesothelioma

What Is Navelbine (Vinorelbine)?

Navelbine® (vinorelbine) is a chemotherapy drug. It belongs to a group of drugs called vinca alkaloids, which were originally derived from the periwinkle plant.

Chemotherapy drugs target different mechanisms that can enable cancer cell growth. Navelbine mainly targets a specific type of protein called a microtubule. Microtubules form part of the physical structure necessary for cellular growth and division.

Navelbine is sometimes used as part of a mesothelioma treatment plan. It has been tested primarily in pleural mesothelioma patients.

Resources for Mesothelioma Patients

Financial Assistance
to Help With Treatment

Financial Assistance to Help With Treatment

• Provide for loved ones
• $30 billion set aside

Request Free Guide

Locate a Top Mesothelioma
Cancer Center

Locate a Mesothelioma Cancer Center

• Find a center near you
• Be better prepared

Get Connected

Connect With a Top
Mesothelioma Doctor

Connect With a Top Mesothelioma Doctor

• Experts near you
• Get matched quickly

Get Connected

How Does Navelbine (Vinorelbine) Treat Mesothelioma?

Navelbine is a chemotherapy drug that interferes with cell growth. Mesothelioma patients may receive it as part of their treatment plan. Navelbine is not a common chemotherapy drug for mesothelioma. However, certain patients may benefit from it. For example, Navelbine may be an option for patients who did not respond well to other first-line treatment options. Mesothelioma doctors can determine if Navelbine treatment might be appropriate.

Navelbine works by targeting a specific protein that enables cell division. It may also cause cancer cell death by interfering with DNA and RNA synthesis. This can hinder cancer cell growth.

Combining Navelbine with other chemotherapy drugs may result in more effective treatment. For example, it is sometimes used with cisplatin. Navelbine and cisplatin use different mechanisms to kill fast-dividing cancer cells. Combining drug mechanisms this way increases the chance of eliminating all cancer cells.

Navelbine (Vinorelbine) for Pleural Mesothelioma

There is currently no standard treatment for mesothelioma using Navelbine. Research has examined ways it may offer benefits for treating malignant pleural mesothelioma. Researchers have investigated Navelbine in the following instances:

• First-line treatment: Navelbine has been used as a first-line treatment. Doctors may use it as a single agent or in combination with another chemotherapy drug.
• Second-line treatment: Navelbine has been used as a second-line treatment. It may be offered as a single agent in this context. It may also be an option for patients who are not eligible for clinical trials.

Studies of Navelbine for pleural mesothelioma have shown a median survival from about 6 to 17 months. This range includes patients treated with Navelbine alone and in combination with other drugs. Several studies have combined Navelbine with more standard forms of mesothelioma chemotherapy treatment.

• One study used Navelbine after a regimen of platinum chemotherapy plus pemetrexed. Median overall survival was about six months.
• A different study used Navelbine as a single agent in first-line treatment. Results showed a 24% response rate, and 41% of pleural mesothelioma patients were alive at one year.
• Another study used Navelbine for pleural mesothelioma patients ineligible for surgery. In the study, researchers combined Navelbine and cisplatin as a first-line treatment. Median overall survival was almost 17 months.

Researchers continue to study Navelbine's use as a mesothelioma treatment. It has U.S. Food and Drug Administration (FDA) approval for non-small cell lung cancer (NSCLC). It is not currently approved to treat other diseases, such as mesothelioma. However, Navelbine has been studied as a treatment option for:

• Breast cancer
• Cervical cancer
• Hodgkin lymphoma
• Mesothelioma
• Multiple myeloma

Currently, Navelbine is not a common form of mesothelioma treatment. But it may be useful in certain situations. Mesothelioma doctors can decide if Navelbine is an appropriate treatment.

Did You Know? The average cost of mesothelioma treatment is $11,000 - $12,000 per month. Over $30 billion in funds have been set aside to help mesothelioma patients with treatment costs. Learn More About Financial Assistance Available

What to Expect During Treatment

Navelbine is one of several different options for mesothelioma chemotherapy treatment. It is administered intravenously. Patients can expect to receive treatment under the supervision of a healthcare professional.

Navelbine may be administered alone or in combination with other chemotherapy drugs. A specialist can determine which combination is most appropriate for a patient. Infusions generally occur over the course of six to ten minutes. They are administered in specific dosages and on a fixed schedule. Dosages may vary based on the type of cancer. Some FDA-approved dosages for NSCLC are as follows:

Healthcare providers attend to patients during infusions. They track vitals to help address problems if they occur. Patients can also alert providers to any discomfort they may feel during their infusion.

Patients may undergo several cycles of treatment. A doctor will determine how many cycles are appropriate. The number of cycles can depend on how well a patient responds to Navelbine. A doctor may decide whether to stop treatment if risky side effects occur.

Preparing for Your Appointment

There are several ways mesothelioma patients can prepare for their Navelbine chemotherapy appointment. Preparation may help reduce stress and discomfort and help avoid any unnecessary complications. In the lead-up to their appointment, patients can ask their doctor questions about treatment.

To prepare for their chemotherapy appointment, mesothelioma patients may also want to:

• Arrange transportation: Patients may feel low-energy or drowsy after their infusion. They may want to arrange a safe ride from the hospital. Transportation services may be available if a friend or family member cannot provide a ride.
• Arrange to bring a companion: Facilities often allow patients to bring a friend or family member to their appointment. Companions can keep patients company, help ask questions and take notes.
• Dress comfortably: Patients can limit discomfort during infusions by dressing in layers and non-constrictive clothing.
• Pack a bag: Patients may get hungry, thirsty or bored during infusions. Packing a bag with certain items may make treatment less uncomfortable. Patients may want to pack snacks, a small meal or a beverage. Crafts and reading materials may also help with boredom.
• Prepare a relaxing post-infusion schedule: Patients may want to spend time resting and recovering after their appointment. A friend or family member may be able to help with chores, errands and meal preparation. Patients may also want to notify their employer that they may need time off.

Healthcare providers may also ask patients about their cancer journey during their appointment. This can help them provide better care. Patients may want to organize their medical documents in one place. This can help avoid stress and create a smoother appointment experience.

Managing Treatment and Follow-Up Care

Patients may go through multiple treatment cycles with Navelbine. Doctors have several ways to manage complications.

Mesothelioma doctors may give patients treatment-management instructions. Patients should make sure to follow any instructions. To take care of themselves during treatment, patients may also want to:

• Avoid large crowds or sick people to help prevent infection
• Drink plenty of fluids to avoid dehydration
• Use caution when doing tasks that need mental alertness until the side effects of Navelbine are known
• Wash hands to reduce the risk of infection

It is also important for patients to attend follow-up appointments with their doctors. These appointments are an opportunity to discuss and address any treatment side effects. Doctors will be able to track mesothelioma patients’ progress. They may draw blood to check blood cell levels and organ functions. Doctors can also help manage side effects and determine if it is safe to continue treatment.

Navelbine (Vinorelbine) Benefits

Navelbine may benefit mesothelioma patients in certain situations. This chemotherapy is generally well-tolerated. This means it has a relatively low incidence of side effects compared to other chemotherapy drugs. As a result, it may be an option for patients who are unable to handle negative side effects associated with other treatments. It may also be useful as a second-line therapy for patients ineligible for clinical trials.

Navelbine is not a common mesothelioma treatment. Its benefits for mesothelioma have not been fully explored. At least one study found promising survival results for patients with pleural mesothelioma. Patients who received a first-line treatment of cisplatin and Navelbine had a median survival of 16.8 months. It is possible that future studies will reveal further benefits. Mesothelioma researchers are always looking for more effective treatments for this rare disease.

Questions About Mesothelioma Chemotherapy Drugs? Ask experienced mesothelioma advocate Jennifer Lucarelli Ask a Question

Navelbine (Vinorelbine) Side Effects

Mesothelioma patients who receive Navelbine treatment may experience side effects. Common side effects include anemia, nausea, vomiting and weakness. Different factors may result in a variety of side effects. For example, drug and therapy combinations may cause different side effects than treatment with Navelbine alone.

Neutropenia is a potential side effect of Navelbine. It is an abnormally low count of white blood cells called neutrophils. If this side effect occurs, doctors may reduce dosage or pause treatment altogether. This condition can make people more susceptible to infection. Discontinuing Navelbine usually has a positive effect on white blood cell count. Doctors generally check patients for neutropenia before each dose of Navelbine.

Patients can ask mesothelioma doctors about side effects before treatment. Doctors can help manage side effects and adverse events as they occur.

Managing Side Effects

A mesothelioma patient’s healthcare team can help manage Navelbine treatment side effects. A patient should speak to their doctor if they experience any adverse reactions. A doctor can assess the situation and provide recommendations to improve the patient’s quality of life.

Nausea and vomiting are common Navelbine treatment side effects. Adjusting nutrition during and after chemotherapy can help manage nausea. A doctor may also prescribe anti-nausea medication. Patients should make sure they take any medication as prescribed.

Another common Navelbine side effect is constipation. Patients are advised to follow a diet rich in fiber and stay hydrated. They may also use stool softeners. A dietitian may be able to recommend a diet plan to help with symptoms and maintain nutrition during treatment.

Certain drugs and supplements may claim to help with treatment side effects. These include:

• Herbs
• Minerals
• Over-the-counter drugs
• Vitamins

Patients should consult their doctor before taking any of these. It is possible they may interfere with treatment. A doctor can determine if a drug or supplement is safe to take with Navelbine.

Who Is Eligible for Navelbine (Vinorelbine)?

Specialists can determine Navelbine chemotherapy eligibility based on several factors. There is currently no standard mesothelioma treatment with Navelbine. Patients should talk with their doctors to determine if they may be eligible for Navelbine treatment. Doctors will know the potential benefits and risks for individual patients.

Navelbine may be used as part of a treatment plan for pleural mesothelioma. Patients may be ineligible for Navelbine for several reasons, including:

• The patient has a poor performance status.
• The patient is pregnant.

Performance status is a measure of a person’s ability to engage in daily activities, rated on a scale from zero to five. Pleural mesothelioma patients with a performance status of zero to two may be eligible to receive Navelbine. A performance status of zero indicates no impairment. Performance status of two indicates the patient is capable of self-care but unable to engage in work activities. Patients rated higher than two may be ineligible for Navelbine.

Earlier lab research suggested tumors lacking the BRCA1 gene might resist Navelbine. A later randomized trial tested this idea in patients. It found BRCA1 status did not predict how well Navelbine worked. Doctors do not currently use BRCA1 testing to decide Navelbine eligibility.

Doctors can help patients explore other treatment options if they are ineligible for Navelbine.

Clinical Trials and Studies on Navelbine (Vinorelbine) for Pleural Mesothelioma

Navelbine mesothelioma treatment is the subject of ongoing studies and clinical trials. Currently, Navelbine is not a common part of a mesothelioma treatment plan. But researchers continue to look for new ways to treat this rare disease.

There is currently no standard second-line mesothelioma treatment after chemotherapy. Researchers in one clinical trial looked at the potential use of Navelbine for this purpose. The trial enrolled 154 pleural mesothelioma patients. It indicated improved progression-free survival for patients treated with Navelbine. Median progression-free survival was:

• Patients treated with Navelbine: 4.2 months
• Patients not treated with Navelbine: 2.8 months

These results suggest Navelbine may be a useful second-line treatment for pleural mesothelioma.

A separate 2022 trial compared Navelbine with a newer drug, anetumab ravtansine, in patients with relapsed pleural mesothelioma. The newer drug did not outlast Navelbine on progression-free or overall survival. This supports Navelbine as a second-line option.

Researchers continue to study new ways to use this chemotherapy drug to deliver more effective treatment. Mesothelioma doctors can determine if Navelbine is appropriate for a patient.